Literature DB >> 8395494

Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.

A L Barry1, P C Fuchs, D M Citron, S D Allen, H M Wexler.   

Abstract

The susceptibility of anaerobic bacteria to two new fluoroquinolones, PD 131628 (the bioactive form of PD 131112 or CI-990) and clinafloxacin (CI-960 or PD 127391), was determined with the agar dilution procedures and two media, and one broth microdilution procedure. Sparfloxacin and ciprofloxacin were also tested by the broth microdilution method. One hundred anaerobic isolates and four control strains were tested by the three methods which gave minimum inhibitory concentrations (MICs) that were essentially comparable, but not identical. With the broth microdilution method, the relative potency of the four fluoroquinolones was: clinafloxacin > PD 131628 > sparfloxacin > ciprofloxacin. For the latter three drugs but not clinafloxacin, the MIC values were often near the proposed interpretive breakpoint concentrations, and thus minor methodological differences frequently influenced the interpretive categories. Replicate agar dilution tests in five laboratories established MIC control limits for each of four control strains: those MIC limits could also be used to define the expected performance of the two alternative methods.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395494     DOI: 10.1093/jac/31.6.893

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Comparative antianaerobic activity of BMS 284756.

Authors:  D B Hoellman; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.

Authors:  Mihaela Peric; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.

Authors:  A L Barry; P C Fuchs; S D Allen; F C Tenover; J H Jorgensen; L B Reller
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

4.  In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters.

Authors:  A L Barry; P C Fuchs; C Thornsberry; J C McLaughlin; S G Jenkins; D J Hardy; S D Allen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

6.  Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

Authors:  M V Borobio; M Conejo; E Ramirez; A I Suarez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 8.  Quinolone activity against anaerobes: microbiological aspects.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1995       Impact factor: 9.546

9.  Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.